{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:39:27Z","timestamp":1781494767810,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Burosumab, a recombinant antibody against fibroblast growth factor 23 (FGF23), is a new therapeutical option for Tumor induced osteomalacia (TIO). To estimate the clinical need and to evaluate the efficacy and safety of burosumab, we conducted a hybrid study composed by a clinical survey and a systematic review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients referring for TIO to the Federico II University were enrolled in our clinical survey. A comprehensive literature search on a Medline, Google Scholar, Google Books, and the Cochrane Library was conducted for the Systematic Review. Data were extracted on 12\/31\/2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the local survey, we collected 10 patients affected by TIO [M: F\u00a0=\u00a05 (50.0%): 5 (50.0%); mean age at symptom onset 57.6 \u00b1 14.3 years]. Two (20.0%) patients received burosumab, obtaining clinical and biochemical improvement. Two who didn\u2019t receive the treatment died. For the systematic review, we collected 42 studies and 49 cases [M: F\u00a0=\u00a019 (44.2%): 24 (55.8%); mean age at onset 36.8 \u00b1 21.3 years; mean age at diagnosis 44.5 \u00b1 22.9 years]. Burosumab reduced clinical symptoms and ameliorates biochemical investigations by normalizing phosphate serum levels. It is also safe and well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Burosumab represents a safe and efficient treatment in TIO patients, to be administered in case of tumor identification while waiting for surgery, and in case of surgical inoperability to manage hormonal FGF23 effect.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1804013","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:14:54Z","timestamp":1775103294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Burosumab an emerging therapy in TIO: a local clinical survey and a systematic review with individual patient data analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Anita","family":"Vergatti","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Abate","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aquilino F.","family":"Zarrella","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fieramosca","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"De Filippo","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine interne et rhumatologie, Service de Sant\u00e9 des Arm\u00e9es, H\u00f4pital National d\u2019Instruction des Arm\u00e9es Percy","place":["Clamart, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Merlotti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Azienda Ospedaliera Universitaria Senese","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Gennari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neurosciences, University of Siena","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Menale","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanfranco","family":"D\u2019Elia","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Rendina","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Federico II University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/B978-0-323-09138-1.00006-1","article-title":"6 - Bone structure and function","volume-title":"Rheumatology","author":"Burr","year":"2015"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac253","article-title":"Tumor-induced osteomalacia: a systematic review and individual patient's data analysis","volume":"107","author":"Rendina","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad690","article-title":"Clinical characteristics of Malignant phosphaturic mesenchymal tumor causing tumor-induced osteomalacia","volume":"109","author":"Abate","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.rdc.2012.03.008","article-title":"Osteomalacia as a result of vitamin D deficiency","volume":"38","author":"Bhan","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00691-6","article-title":"Tumor-induced osteomalacia","volume":"108","author":"Florenzano","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac026","article-title":"Tumor-induced osteomalacia: a comprehensive review","volume":"44","author":"Minisola","year":"2023","journal-title":"Endocr Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf039","article-title":"Real-world efficacy and safety of burosumab in tumor-induced osteomalacia: case series from an early access program","volume":"9","author":"Cadiou","year":"2025","journal-title":"JBMR Plus"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"Jan De Beur","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00198-022-06617-2","article-title":"Appropriate dosing of burosumab in tumor-induced osteomalacia","volume":"34","author":"Colangelo","year":"2023","journal-title":"Osteoporos Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s00223-025-01374-w","article-title":"The diagnosis and therapy of XLH","volume":"116","author":"B\u00f6ckmann","year":"2025","journal-title":"Calcif Tissue Int"},{"key":"B11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1210\/clinem\/dgad440","article-title":"Efficacy and safety of burosumab in X-linked hypophosphatemia","volume":"109","author":"Wang","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","unstructured":""},{"key":"B13","unstructured":""},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-025-04251-4","article-title":"Neoplasms arising at the CIED pocket: a hybrid study combining a case report, scoping review, and clinical survey","author":"Fortunato","year":"2026","journal-title":"Intern Emerg Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jmd2.70044","article-title":"Splenic artery aneurysm in Gaucher disease: a hybrid study combining case report, scoping review, and clinical survey","volume":"66","author":"Manzi","year":"2025","journal-title":"JIMD Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1495930","article-title":"Postmenopausal ovarian hyperandrogenism of surgically treated patients: a case report and scoping review with individual patient's data analysis","volume":"16","author":"Forte","year":"2025","journal-title":"Front Endocrinol (Laus)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1606","article-title":"Fibroblast growth\u00a0factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and\u00a0renal phosphate leak","volume":"91","author":"Rendina","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00223-009-9275-1","article-title":"Bone turnover and the osteoprotegerin-RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases","volume":"85","author":"Rendina","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PloS Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904186","article-title":"Genetic disorders of renal phosphate transport","volume":"362","author":"Pri\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"B21","unstructured":""},{"key":"B22","unstructured":""},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B24","unstructured":""},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"B26","article-title":"Osteomalacia","volume-title":"StatPearls [Internet]","author":"Zimmerman","year":"2024"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.08.035","article-title":"Evaluation of hypophosphatemia: lessons from patients with genetic disorders","volume":"59","author":"Bacchetta","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199112263252604","article-title":"Effects of therapy in X-linked hypophosphatemic rickets","volume":"325","author":"Verge","year":"1991","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01685.x","article-title":"Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"58","author":"M\u00e4kitie","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf047","article-title":"Tumor-induced rickets\/osteomalacia (TIO): diagnostic pitfalls and therapeutic options","volume":"40","author":"Ito","year":"2025","journal-title":"J Bone Miner Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-025-07469-2","article-title":"Oncogenic rickets diagnosed at age 8 and the risk of persistent rickets: a rare case of pediatric-onset tumor-induced osteomalacia","volume":"36","author":"Lasnier-Siron","year":"2025","journal-title":"Osteoporos Int"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4958-24","article-title":"Two cases of tumor-induced osteomalacia resulting in surgical resection during burosumab therapy","volume":"64","author":"Nagata","year":"2025","journal-title":"Intern Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jfma.2024.10.004","article-title":"Effective bone healing after corrective osteotomy in a patient with FGF23-related hypophosphatemic disease using short-term burosumab treatment","volume":"124","author":"Chiu","year":"2025","journal-title":"J Formos Med Assoc"},{"key":"B34","unstructured":""}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1804013\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:14:57Z","timestamp":1775103297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1804013\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":34,"alternative-id":["10.3389\/fendo.2026.1804013"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1804013","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1804013"}}